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Background: Major depressive disorder (MDD) is the leading cause of disability in the developed world, yet
broadly effective treatments remain elusive. Up to 40% of patients with depression are unresponsive to at least two
trials of antidepressant medication and thus have “treatment-resistant depression” (TRD). There is an urgent need
for cost-effective, non-pharmacologic, evidence-based treatments for TRD. Mindfulness-Based Cognitive Therapy
(MBCT) is an effective treatment for relapse prevention and residual depression in major depression, but has not
been previously studied in patients with TRD in a large randomized trial.
Methods/Design: The purpose of this study was to evaluate whether MBCT is an effective augmentation of
antidepressants for adults with MDD who failed to respond to standard pharmacotherapy. MBCT was compared to
an active control condition, the Health-Enhancement Program (HEP), which incorporates physical activity, functional
movement, music therapy and nutritional advice. HEP was designed as a comparator condition for mindfulness-based
interventions to control for non-specific effects. Originally investigated in a non-clinical sample to promote stress
reduction, HEP was adapted for a depressed population for this study. Individuals age 18 and older with moderate
to severe TRD, who failed to respond to at least two trials of antidepressants in the current episode, were recruited to
participate. All participants were taking antidepressants (Treatment as usual; TAU) at the time of enrollment. After
signing an informed consent, participants were randomly assigned to either MBCT or HEP condition. Participants
were followed for 1 year and assessed at weeks 1–7, 8, 24, 36, and 52. Change in depression severity, rate of
treatment response and remission after 8 weeks were the primary outcomes measured by the clinician-rated
Hamilton Depression Severity Rating (HAM-D) 17-item scale. The participant-rated Quick Inventory of Depression
Symptomology (QIDS-SR) 16-item scale was the secondary outcome measure of depression severity, response,
and remission.
Discussion: Treatment-resistant depression entails significant morbidity and has few effective treatments. We
studied the effect of augmenting antidepressant medication with MBCT, compared with a HEP control, for
patients with TRD. Analyses will focus on clinician and patient assessment of depression, participants’ clinical
global impression change, employment and social functioning scores and quality of life and satisfaction ratings.
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Table 1 Components of Mindfulness-Based Cognitive
Therapy (MBCT) and the Health-Enhancement Program
(HEP)
Factor MBCT HEP




Group support X X
Therapeutic attention X X
Session time (135 minutes) X X
Session duration (8 weeks) X X
Physical activity X (e.g. yoga) X (e.g. exercise,
stretching)
Functional movement X
Time equivalent homework X X
Facilitator buy-in to method X X
Note. X indicates the presence of each component in the intervention.
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Major depressive disorder (MDD) is the number one
cause of disability in developed countries and is pro-
jected to become the number two cause of disability
worldwide by 2020 [1,2], yet broadly effective treatments
remain elusive. The World Health Organization (WHO)
Primary Care Study found that 60% of patients treated
with antidepressants still met criteria for depression after
one year of treatment [1]. Treatment-resistant depres-
sion (TRD), the term used to describe cases of MDD
that do not remit with adequate courses of at least two
antidepressant trials [3,4], is unfortunately quite com-
mon [3,5-8]. The seminal Sequenced Treatment Alterna-
tive To Relieve Depression (STAR*D) study found that
only 30% of individuals with MDD will remit with one
full trial of antidepressant medication, and the remission
rates for successive trials are even lower [3,8]. TRD is as-
sociated with greater disability, mortality, morbidity,
somatic symptoms, risk of relapse and societal cost than
those who suffer from non-resistant forms of depression
[4,9,10]. Hence, there is an urgent need for innovative
and effective treatments.
Mindfulness-Based Cognitive Therapy (MBCT) is a
group-based, 8-week, mind-body intervention that inte-
grates mindfulness meditation with concepts of cognitive
behavioral therapy (CBT) and was specifically developed as
a relapse prevention intervention for MDD [11]. MBCT’s
approach is distinctive, as it focuses on the cultivation of
effective methods to relate to depressive thoughts and feel-
ings, rather than challenging or changing specific cogni-
tions as taught in CBT. MBCT teaches patients to relate to
their unpleasant thoughts, feelings, and bodily sensations
as temporary passing events in the mind, rather than iden-
tifying with them or treating them as accurate reflections
of reality.
Several studies have investigated MBCT as an augmen-
tative treatment for acute depression. As an augmentor
to medications, results indicate that MBCT has similar
efficacy to CBT [12,13]., MBCT augmentation was more
efficacious than antidepressant management alone in re-
ducing the residual symptoms of chronic depression
[14,15] and improved outcomes in dysthymia compared
to imipramine monotreatment [16]. Open label trials of
MBCT augmentation of antidepressants for TRD showed
effect sizes of 1.0 (Cohen’s D) in studies by both Kenny
and Williams [12] and Eisendrath et al., [13], making the
investigation of MBCT as a potentially effective augmen-
tative treatment for TRD worth further examination in a
full randomized controlled trial (RCT).
Research objectives
The primary objective of this trial was to evaluate whether
Mindfulness-Based Cognitive Therapy is an efficacious
treatment for reducing depressive symptoms in adultswith TRD. Individuals with TRD may be excellent candi-
dates for MBCT [12,17], yet previous RCTs evaluating
MBCT for depression failed to include an active com-
parator condition, limiting the results by not control-
ling for the non-specific factors (e.g., group support,
homework, and facilitator attention) potentially associ-
ated with MBCT efficacy. With this limitation in mind,
an active control condition, originally developed to be
a structurally equivalent, comparison condition for
studies Mindfulness-Based Stress Reduction MBSR) –
the Health-Enhancement Program (HEP) was selected
for this trial.
The study’s secondary objectives were to assess whether
MBCT would be more effective than HEP in reducing
symptoms of functional disability and improving overall
quality of life and satisfaction and to examine potential
mediators of MBCT treatment response. Finally, the study
aimed to evaluate whether MBCT’s potential treatment ef-
fects related to depression severity, functional status, and
mindfulness would be sustained during 1-year follow-up
phase.
Methods/Design
This study is a single-site, randomized, controlled clin-
ical trial of MBCT augmentation of Treatment-as-Usual
(MBCT + TAU) and HEP augmentation of TAU (HEP +
TAU). TAU consisted of standard medication manage-
ment for depression. In a single-blind fashion, partici-
pants were aware of treatment allocation but were blind
to study hypothesis. Research assistants (RA’s) respon-
sible for assessment of depression severity, were blind to
individual randomization assignments. See Table 1 for a
list of inclusion and exclusion criteria.
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The two treatments, MBCT and HEP consisted of 8
weekly classes, each lasting 2.25 hours. In addition to at-
tending weekly classes, participants in both groups were
encouraged to complete 45 minutes of homework six days
per week for the duration of the 8-week treatments.
Both interventions were conducted in a group format
with 6–12 participants per group and were led by two
facilitators extensively trained in their respective techniques.
MBCT is a manualized treatment that combines train-
ing in mindfulness meditation with elements of cognitive
therapy. For the purpose of this study, MBCT was
adapted from the original manual developed by Segal
et al. [11] with modifications for TRD, the details of
which are published elsewhere [13]. These modifications
are believed to promote enhanced emotional regulation
specific to TRD through increasing an individual’s non-
judgmental awareness of their present moment experi-
ence [13]. MBCT teaches skills that encourage patients
to disengage from habitual (“automatic”) dysfunctional
cognitive routines, in particular depression-related ru-
minative thought patterns, as a way to reduce current
symptoms, future risk of relapse and recurrence [16].
Through guided meditation practices and activities, par-
ticipants are taught to develop more present-focused,
non-judgmental awareness of their thoughts and feelings
instead of focusing on the content of them [11,14,15,18].
It is theorized that the same cognitive processes known
to make individuals prone to depression relapse are also
active in perpetuating depression once it is established
[12] and are a primary driver of TRD.
HEP was developed as a collaborative effort between
the Waisman Laboratory for Brain Imaging and Behav-
ior at the University of Wisconsin – Madison and the
University of Wisconsin Hospital and Clinics Sports
Medicine Center in consultation with the National
Center for Complementary and Alternative Medicine
(NCCAM). HEP was designed to provide health bene-
fits to participants while omitting any components of
mindfulness and was developed specifically as a con-
trol condition for studies of MBSR [19,20]. Originally
used as a control condition for stress reduction in
non-clinical samples, we adapted HEP to be an active
comparison condition for individuals with TRD. HEP
provides participants with intensive training in aerobic
exercise (i.e. walking), functional movement, music
therapy, and nutritional advice. Classes encourage par-
ticipants to engage in experiential, didactic exercises
which include exercise, functional movement, food
journaling, song-writing, guided imagery and drawing.
Participants are provided with psycho-educational lectures
on topics related to aerobic exercise, novel functional
movement patterns, nutrition, establishing a balanced diet,
and how these health elements can impact mood.Similar to the MBCT program, HEP participants were
encouraged to individualize the program to meet their
unique needs and symptoms. They were asked to attend all
weekly sessions and engage in approximately 45 minutes of
homework assignments on the remaining 6 days of the
week. A portion of each class was devoted to participants
describing their experience of the group and the “barriers”
to treatment that arose in the completion of the formal
and informal (i.e. homework) practices assigned by facilita-
tors, which mirrors the same model used in MBCT. After
the completion of the program, participants were provided
with community resources to continue their practices, just
as referral resources were provided during the final MBCT
session.
In summary, HEP provides a credible comparator con-
dition for MBCT by controlling for features of MBCT
such as class participation, overall time invested, attention,
group process, social interaction and support, homework,
and experiential participation through in-class exercises
(Table 1). A comparison of the course content by session
for each intervention is outlined in Table 2. Study partici-
pants were not engaged in individual or group psychother-
apy during the study treatment time period.
TAU augmentation for both treatment groups was
identical and consisted of medication management and
supportive counseling delivered by third or fourth year
psychiatric residents, attending psychiatrists or primary
care physicians. Supportive therapeutic approaches aid
in patients addressing problems without direct input
from providers. Providers offer patients encouragement
and guidance but do not engage in any therapeutic strat-
egy other than active listening and offering support by
focus on patients’ problems and concerns. Routine TAU
visits are less than 30 minutes in duration and at inter-
vals of one to three months. Participants were allowed
to make medication changes during the acute and
follow-up periods, with reporting of such changes on a
regular basis. These changes will be incorporated into
the analyses.
Sample size
To estimate sample size, effect sizes were based on out-
comes from previous studies and our pilot data [15,21-24].
In a review of 21 mindfulness-meditation interventions,
Baer [23] found an average effect size of .90 for depressive
symptom reduction. In examining the relapse rates of indi-
viduals receiving MBCT versus TAU, Teasdale et al. [14]
found an effect size of .59 and Ma et al. [15] of .88 for par-
ticipants with a history of 3 or more depressive episodes.
Our pilot data indicated an average effect size of 1.13,
which compared similarly to Kenny’s effect size of 1.03 in a
TRD population [12]. Finucane et al., working with a more
severely depressed population, found an effect size of 1.54
[25]. Kingston et al. found an effect size of 1.07 in reducing
Table 2 Mindfulness-Based Cognitive Therapy (MBCT) and the Health Enhancement Program (HEP) Content by Session
Session MBCT HEP
1 Automatic Pilot: focuses on becoming aware in the present moment. Problems in Improving Health: focuses on physical fitness, functional
movement exercises, and music and imagery.
2 Dealing with Barriers: Participants discuss problems in focusing
attention and are encouraged to adopt an attitude of “letting go”
of self-criticism and judgment.
Physical Activity to Enhance Well-being: Physical activities focus on
posture and alignment as ways to optimize function. Supportive
music imagery exercises are used to improve sense of well-being.
3 Mindfulness of the Breath: Participants complete a sitting meditation
in which they shift from focusing on body sensations to focus on
their breath in a sitting posture. Mindful movement techniques are
begun.
Understanding Dietary Guidelines: Participants engage in a lecture
and discussion series about basic nutrition principals. Diet journaling
is reviewed and demonstrated as a way to better understand
healthy food choices.
4 Staying Present: Concepts of attachment/avoidance to pleasant/
unpleasant sensations, moods, and thoughts are discussed. The
“three-minute breathing space” is taught as a simple intervention
for use throughout the day.
Fine-tuning Dietary Choices: Participants learn the use of the USDA*
My Pyramid Food Tracker Program and behavioral changes are
discussed as a way to meet dietary goals.
5 Allowing/Letting Be: Focus is on allowing experiences “to be”
without judging or trying to change them.
Adapting to an Unpredictable Environment- Part I: Activities focus
on functional movement and alignment. Supportive Music Imagery
focuses on responding to the environment in creative ways.
6 Thoughts Are Not Facts: Focus is on viewing thoughts as mental
events and not concrete facts.
Adapting to an Unpredictable Environment – Part II: Activities such
as walking, jogging and stretching are discussed as participants are
encouraged to respond to the environment in creative ways to
enhance well-being.
7 How Can I Best Take Care of Myself: Participants learn their unique
warning signs of depression relapse or worsening.
Responding to the Environment in Creative Ways: Participants learn
the kinetic chain of functional movement and build group cohesion
through group song writing exercises.
8 Using What Has Been Learned to Deal with Future Moods:
Participants discuss how they will keep the momentum of their
practice going. Therapists distribute information about settings
where group mindfulness practice can be continued.
Support for Continuing Practice: Participants review the course and
plan for maintaining gains including all components of HEP.
Participants review their goals with the dietician.+
*USDA = United States Department of Agriculture.
+ The original HEP protocol was amended to include Nutrition in session 8.
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significant differences in effect on depression in a compari-
son of HEP and MBSR [19,20]. Using the formula provided
by Donner and Klar [27], we estimated sample sizes to de-
tect response to the intervention (MBCT+TAU would be
superior to HEP +TAU on depression outcomes). Results
indicated sample sizes ranging up to approximately 50 per
condition. A total sample of 124 participants were regarded
as necessary to provide 80% power to detect a moderate ef-
fect size in the face with an estimated attrition of approxi-
mately 20%, similar to our rates of attrition in clinical
MBCT groups.
Recruitment
Study recruitment was conducted between September
2009 and September 2013 in outpatient psychiatry and
general medicine clinics at the University of California,
San Francisco (UCSF) Medical Center and the out-
patient psychiatry clinic at Kaiser Permanente in San
Francisco. Both recruitment sites were housed in large
medical centers that serve an ethnically diverse population
of privately and publically insured adults in the San
Francisco Bay Area. To further contribute to the diversity
of the patient sample, community locations were added to
the recruitment plan at later stages in the study, as well as
clinics at San Francisco General Hospital.Recruitment methods were approved by the institu-
tional review board (IRB) at the UCSF Human Research
Protection Program (#10-00455). For patients served
through general medicine clinics at UCSF, approval was
obtained to introduce the study with a letter from the
principal investigator (PI) to prospective research sub-
jects who had been identified through a query of patient
medical record databases to have an ICD-9 code of de-
pression and/or a medical history of taking antidepressant
medication. Patients receiving the letter were invited to
opt out of the study by mail within two weeks of receiving
the letter. Patients who chose not to opt out were con-
tacted by telephone by a RA to assess interest and eligibil-
ity to participate in the study. Potential candidates from
other recruitment sites were referred by various methods,
including research flyers, referrals from treating physi-
cians, online announcements and print advertisements
posted in public spaces and inside of buses and other pub-
lic transportation vehicles in the Bay Area.
Eligibility criteria (inclusion and exclusion criteria)
Participants age 18 or older were required to meet DSM-
IV criteria for major depressive disorder and have a total
score of 14 or higher on the clinician-rated, 17-item
version of the Hamilton Depression Severity Rating
Scale (HAM-D) [28] to be eligible for the study. To
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taking antidepressant medications with evidence of at
least two adequate antidepressant trials prescribed dur-
ing the current depressive episode. Participants were
excluded (Table 3) from the study for the following
reasons: they a) met DSM-IV criteria for bipolar dis-
order, obsessive compulsive disorder, or post-traumatic
stress disorder (other comorbid Axis I conditions were
noted but not cause for exclusion); b) had a history of
schizophrenia or other psychotic symptoms; c) were
imminently suicidal, a danger to others or were currently
exhibiting self-injurious behavior; d) met DSM-IV criteria
for alcohol or substance abuse or dependence within
3 months of study entry; e) were currently practicing
meditation more than once per week or yoga more than
two times per week; f ) had cognitive impairment as evi-
denced by a score of < 25 on the MMSE; g) were in con-
current individual or group psychotherapy and were not
willing to discontinue treatment for the 8-week duration
of study treatment; h) had significant or unstable medical
illness that would limit participation in HEP; or i) did not
have adequate English language comprehension.
Assessment of eligibility and informed consent
Interested individuals underwent initial screening for eli-
gibility using a brief, structured telephone interview.
Those with depressive symptoms being treated with an-
tidepressants medications and not meeting exclusion cri-
teria in Table 3 were invited for an in-person screening
evaluation to determine eligibility and review informed
consent. Psychological eligibility criteria such as depres-
sion severity and psychiatric history were assessed by a
licensed mental health professional on the researchTable 3 Eligibility criteria for the PATH-D study
Inclusion criteria
- Age 18 or older
- Current major depression (DSM-IV-TR criteria)
- HAM-D total score ≥ 14
- Total ATHF Intensity score ≥5 for 2 or more antidepressant
medications
- Evidence of two failed adequate antidepressant trials in the current
depressive episode
- Current use of antidepressants
Note. HAM-D = Hamilton Depression Rating Scale; ATHF = Antidepressant Treatment
Rating Scale.
*Axis I anxiety disorders are not excluded as they are highly co-morbid with depres
anxiety disorders were not excluded in the original MBCT studies nor in the STAR*Dteam who had undergone intensive standardized training
provided by one of the authors. Prior to the first assess-
ment session, RAs explained the trial to participants by
reviewing the study procedures, treatment interventions
and required time commitment, and participants were
given an opportunity to ask questions before signing in-
formed consent. Participants were reminded that study
participation was voluntary and that they had the right to
withdraw from the research at any time without disrup-
tion to their usual care.
During the screening assessment, consenting participants
provided information about their socio-demographic sta-
tus. Assessment of depression severity and psychiatric his-
tory was conducted through a semi-structured clinical
interview using the Structured Clinical Interview for DSM-
IV (SCID) [29], the HAM-D [28] and the Clinical Global
Impression Severity (CGI-S) [30] scale. The SCID personal-
ity inventory for Axis II disorders (SCID-II) was used to as-
sess the presence of personality disorders, and the Mini
Mental Status Exam (MMSE) [31] was used to assess cog-
nitive function and to rule out cognitive or developmental
delays that might interfere with treatment. Treatment his-
tory and adequacy of antidepressant medication treatment
was evaluated using the Antidepressant Treatment History
Form (ATHF) [32]. Confirmation of at least 2 adequate tri-
als of efficacy with a minimum total intensity score of
5 points or greater was required for study entry. In
cases where treatment history or medication compli-
ance was in question, RAs received informed consent
from participants to review medical records and/or
contact prescribing physicians to confirm adequacy of
treatment. Finally, participants were asked to complete
the self-report Cumulative Illness Rating Scale (CIRS)Exclusion criteria
- Clinically significant suicide risk
- History of schizophrenia or psychotic symptoms
- Bipolar disorder
- Obsessive compulsive disorder
- Alcohol or substance abuse or dependence within the past 3 months
- Insufficient ability to understand or read English
- MMSE total score < 25
- Severe medical illness determined by the CIRS
- History of meditation practice or currently meditation more than 1 time
per week
- Currently practicing yoga more than 2 times per week
History Form; MMSE =Mini Mental Status Exam; CIRS = Cumulative Illness
sion. This study is designed to approximate a real world, clinical setting, and
trials.
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any one item required further evaluation from the re-
search team to ensure participants could perform the
required physical activities in HEP. Table 4 outlines all
measurements and a complete list of time points of
administration.
Data obtained during the intake interview was pre-
sented in a weekly research conference where the principal
investigator reviewed eligibility criteria on a case-by-case
basis to make determinations about participants’ eligibility
for enrollment.
Randomization and baseline assessment
The unit of randomization was the patient, and
randomization tables were stratified by gender toTable 4 Eligibility and outcome measures
Category/ Week of measureme
Measure # Item Screen
Eligibility and demographic measures
Contact Info\Demographic data - X
Mini mental status exam 11 X
Structured clinical interview for diagnosis of axis I/II - X
Antidepressant treatment history form - X
Cumulative illness rating scale X
Depression outcomes
Hamilton depression rating scale 17 X
Quick inventory of depression symptomatology 16
Clinical global impressions scale 2
SCID mood module for major depression -
Longitudinal interval follow-up evaluation -
Functional status outcomes
Health status-short form 12 12
Work and social activity scale 5
Quality of life enjoyment satisfaction questionnaire 15
Measures of mediation/moderation
Therapeutic rationale scale 4
State trait anxiety inventory 40
Perceived stress scale 14
Childhood trauma questionnaire X
Ruminative response scale 22
Acceptance and avoidance questionnaire 10
Five facet mindfulness questionnaire 30
Experiences questionnaire 20
Self-compassion scale 26
Medication/Psychotherapy change form -
Homework summary log -
*CI = Clinical interview; PQO = Patient questionnaire online.ensure balanced assignment. Patients were random-
ized during the baseline assessment, which occurred
within two weeks of the commencement of treatment (see
Figure 1. Study Design and Participant Flow). Baseline as-
sessments served two purposes: 1) to ensure that patients
continued to meet eligibility criteria for MDD with
scores ≥ 14 on the HAM-D and 2) to serve as the primary
data collection point (see Outcome Measures section). Pa-
tients who reported improved depressive symptoms during
the baseline interview with HAMD total scores < 14, were
not randomized to treatment and told that they could be
reassessed for a future intervention cohort should their de-
pression symptoms relapse. Participants who continued to
be eligible on measures of depressive severity were then
randomly assigned to either MBCT +TAU or HEP +TAU.nt point Method of







X X X X X X CI
X X X X X X X X X X PQO
X X X X X X CI
X X X X CI
X X X X CI
X X X X X X PQO
X X X X X X PQO
X X X X X X PQO
X X PQO
X X X X X X PQO
X X X X X X PQO
PQO
X X X X X X PQO
X X X X X X PQO
X X X X X X PQO
X X X X X X PQO
X X X X X X PQO
X X X X X X X X X X CI
X X X X X X X X X PQO
Figure 1 Study design of randomized control trial of Mindfulness-Based Cognitive Therapy (MBCT) versus the Health-Enhancement
Program (HEP) in adults with treatment-resistant depression.
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Outcomes were assessed at baseline, weeks 1–7, at the end
of treatment (week 8) and at weeks 24, 36 and 52 during
the long-term follow-up phase. Data was obtained from
patient questionnaires completed online and through clin-
ical RA ratings, which were confirmed with chart review of
medical records when necessitated.Primary and secondary outcome measures
The primary outcome measurement was improvement of
depression severity after 8 weeks, as measured through
change in HAM-D total scores from pre- to post-treatment,
treatment response (scores ≥ 50% decrease from baseline)
and remission (post-treatment scores ≤ 7). Length of treat-
ment efficacy, a secondary outcome, was assessed up to
1 year after baseline using HAM-D scores, response and re-
mission rates by measuring rate of depression relapse using
the semi-structured Longitudinal Interval Follow-up Evalu-
ation (LIFE) [35]. The participant-rated 16-item Quick In-
ventory of Depressive Symptomatology (QIDS) [36] was
used as a secondary measurement to assess change in de-
pressive severity, response (scores ≥ 50% decrease from base-
line) and remission (scores ≤ 5) during the same treatment
and follow-up time period.
Functional status and quality of life were additional
secondary outcomes measured using the SF-12 Health
Survey [37,38], the Work and Social Adjustment Scale(WSAS) [39], [40] and the Quality of Life, Enjoyment,
and Satisfaction Questionnaire (Q-LES-SQ) [41].Mediators, moderators and potential covariates
A number of other psychometric variables believed to be
associated with mindfulness were investigated and mea-
sured at baseline, during mid-point (week 4), after the
end of treatment (week 8) and the long-term follow-up
weeks 24, 36, and 52. The following potential mediators
related to MBCT were measured: mindfulness with the
Five Facet Mindfulness Questionnaire [42]; experiential
avoidance with the Acceptance and Action Question-
naire (AAQ) [43]; rumination with the Ruminative Re-
sponse Scale (RRS) [44,45]; and self-compassion with
the Self-Compassion Scale (SCS) [46].
Psychiatric factors that may impact depression severity
and resistance such as early age of depression onset, number
of recurrences, poor treatment outcomes (e.g. incomplete
remission) and co-morbid psychiatric illness (e.g. anxiety
disorders [47] or personality disorders [48]), will be included
in the analysis as covariates [49]. Also included will be other
factors known to be moderators of depression treatment
outcomes. These include demographic factors such as mi-
nority status, ethnicity and lower socio-economic status [50]
and stress, both current [51,52] and a childhood history of
stress [53] (trauma, abuse, neglect) which were collected
during the baseline assessment.
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utilized in treating persisting or worsening depression in
the STAR*D studies [3,8]. Changes were tracked during
the 8-week treatment and over the 52 week follow-up
through patient report and chart review. Alternate forms
of treatment (i.e. individual psychotherapy, group psycho-
therapy, electroconvulsive therapy, etc.) for depression
was tracked after the treatment-phase of the study
through patient report and interview. These treatments
will be analyzed as covariates as well as secondary out-
comes, similar to the aforementioned medication changes.
Treatment expectancy to assess potential moderating
effects of positive expectancy was measured through the
Treatment Rationale Scale [54-56], which participants
completed after the first and final sessions (weeks 2 and 8).
Changes in psychotropic medications including antidepres-
sants, benzodiazepines and mood stabilizers were tracked
at every assessment time point using a medication evalu-
ation form. Lastly, participant engagement in treatment
was measured through attendance and total time spent
completing homework and related activities outside of
class. A complete list of the outcome measures, measure-
ment points and assessment methods for the study are
summarized in Table 4.
Treatment adherence and fidelity assessment
Adherence to treatment was defined by measuring the
received therapy dose through number of sessions
attended. In the current trial, a completer of treatment
was defined as participation in at least five out of eight
sessions.
Group leaders digitally recorded all treatment sessions,
and recordings were sent to independent evaluators not
affiliated with the university or part of the research team.
MBCT adherence and competency was provided by an
expert in MBCT who reviewed 3 randomly selected ses-
sions from each treatment cohort. For the control condi-
tion, external monitoring of treatment HEP adherence
and facilitator competency was completed by a HEP ex-
pert who also reviewed 3 randomly selected sessions
from each treatment cohort. Internal treatment adherence
and competency for both interventions was assessed by
the principal investigator who reviewed the same 3 ran-
domly selected sessions. The MBCT Adherence Scale
[57], an instrument used in the original studies of MBCT,
was used to assess treatment fidelity. Inter-rater reliability
ranges from 0.59 for the Cognitive Therapy subscale and
.97 for the Mindfulness subscale, and 0.82 for global rat-
ings. Competence in delivering MBCT is rated with a
newly developed measure, MBCT Competence Scale [13].
This 10-item instrument uses a scale from 0–5 to assess
each facilitator’s skill in delivering the treatment. Treat-
ment Fidelity in HEP was assessed using the HEP Ad-
herence Scale. The HEP Adherence Scale is a newlydeveloped scale and is modeled after the MBCT Ad-
herence Scale. It is a 17-item instrument where items
are score from 1 to 3. Competence in delivering HEP
was rated with a newly developed instrument, the HEP
Competency Scale. This is a 10-point scale for rating
group facilitator skill and expertise in delivering the
intervention. Because the HEP Adherence Scale, HEP
Competency Scale, and MBCT Competency Scale have
not been previously validated, they will serve as tem-
plates for assessment in this study and pilot data for
future research. Based on reviews and results of adher-
ence and competency measures, feedback was provided
to group leaders during weekly supervision meetings.
Data safety and monitoring plan
In consultation with NCCAM, an independent Data
Safety Monitoring Board (DSMB) was established to
oversee all study activities to ensure the safety of partici-
pants, the validity of our findings and the need for fur-
ther data collection. Three categories of patient safety
concerns were highlighted for this study: 1) increased
depression severity; 2) risk to safety through self-harm
and increased suicidal ideation and; 3) study withdrawals
that were potentially or definitely related to specific fac-
tors in each treatment intervention. Regarding suicidal
ideation among enrolled participants, when patients
responded positively to the suicidality questions on the
HAM-D and QIDS or experienced a 1 or greater point
increase from their baseline scores, RAs initiated the fol-
lowing actions they: 1) they notified the PI; 2) provided
patients with referrals to crisis hotlines; 3) discussed
with patients whether the patient had notified their pre-
scribing physician or mental health provider about their
symptoms and; 4) in some cases, where the PI deemed
that more clinical contact was warranted, they corre-
sponded via telephone and/or sent confidential letters
and email correspondences to providers notifying them
of their clinical impressions.
Planned analytic approach
The primary outcome measure of the HAM-D will be
compared between participants randomized to the
MBCT + TAU and the HEP + TAU groups using a
mixed-effects statistical model [58,59]. Mean levels of
severity, and response and remission rates at week 8 and
bivariate measures will be compared between treatment
conditions using logistic regression models with general-
ized estimating equations to correct for interdependence
resulting from group membership. The secondary out-
come measures of the QIDS-SR and CGI will be com-
pared using the same methodology but replacing the
HAM-D with the QIDS-SR and CGI severity measures.
We will also assess relapse occurrence in both arms using
the LIFE interview at weeks 24, 36 and 52.
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functional status as a secondary outcome will be assessed
using similar models to the methods used to test the re-
duction in HAM-D17 scores. For each of the four scales,
scores at week 8 will be compared between randomized
conditions using a mixed-effects statistical model, which
will include effects for randomized condition, therapy
group and baseline disability score. The test of the esti-
mated parameter for treatment condition will be a direct
test of this hypothesis. Mediating effects of the relation-
ship of treatment assignment with outcome will be tested
using a series of linear regression models. Putative me-
diators, enhanced mindfulness (FFMQ), enhanced self-
compassion (SCS), diminished rumination (RRS) and
decreased experiential avoidance (AAQ) will be assessed
at weeks 4, 8, 24, 36, and 52. We will also assess persist-
ence of treatment changes in depression (HAM-D, QIDS-
SR, CGI), functional status (SF-12, WSAS, Q-LES-Q-SF),
mindfulness (FFMQ), rumination (RRS), self-compassion
(SCS) and avoidance (AAQ) at weeks 24, 36 and 52 by
analyses parallel to those outlined for testing Hypotheses
1 and 2 using data from the weeks 24, 36, and Week 52.
Mixed-effects and logistic regression models using a gen-
eralized estimating equation (GEE) will allow direct testing
of these effects. Moderating factors (e.g. age of depression
onset, prior poor treatment outcomes, co-morbid psychi-
atric diagnoses and other socio-demographics) associated
with TRD will also be included in the model.
Additional secondary analyses will test for effects of
time. These models will also include indicator variables
of any additional treatments (e.g. HEP participants’
crossing over to take MBCT outside of the research),
medication changes after the end of acute treatment be-
fore the 24, 36 and 52-week follow-ups and also whether
or not patients began new psychotherapeutic interven-
tions after treatment or continued formal meditation
practices.
Based on the extent and nature of missing data (out-
comes, predictors, baseline, and items from scales), we will
use one of several strategies for data analysis. We anticipate
that the majority of missing data will result from partici-
pant attrition. In this case, we will know the randomization
assignment and have data from some, but not all, of the
planned assessments. Our primary approach to dealing
with this monotone missing data pattern will be a pattern-
mixture modeling approach [60]. We may also be missing
some data on predictors, even in the absence of participant
attrition. Our primary method for dealing with missing
predictor values will be multiple imputation using a regres-
sion modeling approach [60]. This method is superior to
simpler methods such as using group means for missing
data. In order to limit attrition, we will provide an incentive
in the form of an assessment payment schedule to increase
motivation to complete all assessments.Discussion
Treatment-resistant depression is a condition associated
with high rates of disability, chronicity, reoccurrence and
failed response to antidepressant treatment [3,8]. Through
decreased workforce productivity and disability, the eco-
nomic burden caused by refractory depression is enor-
mous [10,61]; hence the importance of finding effective
treatment modalities for this population is clear and of
vital public health interest. This investigation represents
the first RCT to evaluate MBCT for TRD. Results from
this study will address whether MBCT is superior in
reducing depression severity after 8 week treatment
and improving relapse and remission rates over time in
comparison to a credible comparator condition, devel-
oped to control for non-specific treatment effects. If
successful, this study will identify an augmentation
treatment for a large, hard-to-treat population for
whom few treatments have been effective.
After analysis, we will be able to assess whether the
specific constructs of a mindfulness-based intervention,
such as the putative mediators in MBCT (increased
mindfulness, self-compassion and decreased rumination
and experiential avoidance) are enhanced more after an
8-week treatment with MBCT compared with HEP, and
whether they are associated with positive treatment out-
comes. We will also be able to evaluate whether treatment
gains between groups (i.e. reduced depression severity, in-
creased functional status) are retained during a 1-year
follow-up and whether differential effects might be medi-
ated by the specific constructs of MBCT listed above. Fi-
nally, we will be able to assess whether participant
expectancy, treatment adherence (i.e. number of sessions
attended), and compliance (i.e. number of minutes of
homework completed) predicted treatment outcomes.
Limitations
The TAU intervention has some variance because we
allowed medication changes to take place, which in-
creases the possibility of wash-out effects of MBCT or
falsely amplifying its effects. Moreover, antidepressants
alone are also well documented to be associated with pla-
cebo effects, although these appear to be reduced in a TRD
population [62]. Because our aim was to show that MBCT
is an effective augmentation strategy and because we wanted
trial results to be widely generalizable in light of routine
clinical practice, we permitted some flexibility in medication
changes. We anticipate that randomization and statistical
analysis will control for this variance and allow us to com-
pare the impact of medication changes in both arms.
The current investigation lacks a 3rd arm or wait-list
control condition, which limits the ability to determine
whether factors unrelated to treatment, such as time or
life events effects were associated with treatment effects.
We will however, be able to compare our outcomes to
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Williams [12] and Eisendrath et al., [13]. While we
expect the association to be modest, we predict that
treatment expectancies or patients’ initial beliefs about
the success of either intervention could influence treat-
ment outcomes. The current investigation lacks a measure
of treatment preference, which could have played a pre-
dictive role in affecting clinical outcomes.
Summary
In summary, the results of this trial will address whether
MBCT, previously shown to be effective for relapse preven-
tion, may be an effective augmentation therapy for patients
with TRD in active depressive episodes. In addition, this is
the first RCT to compare whether MBCT is more effective
in reducing depression, rates of relapse and disability when
augmented by medications (TAU) than an active compara-
tor condition; thereby isolating the elements of MBCT that
might be most salient. In particular, the study will highlight
whether mindfulness or other features of the interventions
play important roles in the outcomes. In addition, the
study will shed light on which MBCT factors play mediat-
ing roles in producing its effects. National self-report sur-
veys have found complementary and alternative techniques
such as mindfulness, are being used by 41% to 54% [63] of
individuals with depression, indicating that there is sub-
stantial public demand for mindfulness-based treatment
interventions. Consequently we believe the results of this
study will have significant applications for depression care
by informing providers about targeted, population-based
non-pharmacological interventions strategies that may also
be appealing to TRD patients.
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